Vol. 18/No. 08 | OncologyLive

Next-Generation Therapies in CRPC Take Aim at AR Resistance

April 19, 2017

As a wealth of research has shown in the past several years, therapies that target the androgen receptor pathway in patients with castration-resistant prostate cancer encounter complex mechanisms of resistance including the likelihood that more than 1 such signaling network is active in each individual.

After a 10-Year Lull, Trials in Liver Cancer Show Promise

April 18, 2017

A panel of experts discusses standard treatments for early-stage and advanced liver cancer, reviews investigational second-line therapies, and expresses optimism that some of these therapies may one day improve outcomes for patients.

Clinicians Must Evaluate Evidence Needed in Real-World Practice

April 17, 2017

Research on a scalp-cooling device to help patients with breast cancer avoid hair loss during chemotherapy illustrates this question: what level of evidence might individual clinicians require before they would suggest, recommend, or support the use of a particular approach in treating patients outside the realm of the mandates of governmental agencies or payers?

BCL-2 Inhibitors May Provide Avenue of Attack Against High-Risk Neuroblastoma

April 17, 2017

Investigators at Virginia Commonwealth University Massey Cancer Center discuss the current treatment for children with high-risk neuroblastoma including high-dose chemotherapy, surgery, stem cell transplantation, radiation therapy, isotretinoin, and immunotherapy.

Novel Drug Targets Cancer Stem Cell Pathway in Metastatic CRC Trial

April 17, 2017

The international CanStem303C trial is evaluating the combination of napabucasin, the most advanced cancer stemness inhibitor in development, with FOLFIRI chemotherapy in patients with previously treated metastatic colorectal cancer.

Staying Vigilant

April 13, 2017

Survivorship care for patients who have had cancer is a relatively new phenomenon in the oncology field. After all, the transformation of many cancers from fatal to chronic conditions has occurred in less than a decade. Not surprisingly, then, the science of survivorship care is still evolving, too.